Home>>Signaling Pathways>> Others>>TOK-8801

TOK-8801

Catalog No.GC31957

TOK-8801 is a synthesized dihydroimidazothiazole carboxamide and is under development as an immunomodulator.

Products are for research use only. Not for human use. We do not sell to patients.

TOK-8801 Chemical Structure

Cas No.: 105963-46-0

Size Price Stock Qty
1mg
$414.00
In stock
5mg
$827.00
In stock
10mg
$1,471.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Product Documents

Quality Control & SDS

View current batch:

Protocol

Cell experiment:

Spleen cells (2×105) or thymus cells (2×105) from BALB/c mice are cultured with Con A (1 or 5 μg/mL) or LPS (10 μg/mL) in 0.2 mL of RPMI-1640 medium containing 5% FCS using round-bottomed microculture plates with 96 wells for 2 days and are pulsed with 0.5 μCi of 3H-TdR for an additional 18 hr. Then, cells are harvested on glass fiber fillters, and 3H-TdR incorporation is measured in a liquid scintillation counter. TOK-8801 is added at the initiation of the culture[1].

Animal experiment:

Male BDFI mice are used in this study. Control mice are maintained without food or water while counterparts are under the condition of restraint-stress. On the next day, the mice are immunized with 5×108 SRBC intraperitoneally. Immediately, 24 hr and 48 hr after the immunization, TOK-8801 is orally given at doses of 0.02, 0.1 and 0.5 mg/kg/day. All administrations are done after a starvation for 6 hr. Four days after the immunization, splenic anti SRBC PFC are assayed[1].

References:

[1]. Fujiwara M, et al. Immunomodulatory activity of the newly synthesized compound TOK-8801 (N-(2-phenylethyl)-3,6,6-trimethyl-5,6-dihydroimidazo[2,1-b]thiazole-2- carboxamide). Jpn J Pharmacol. 1989 Dec;51(4):549-54.
[2]. Shibata K, et al. Immunomodulatory effect of a newly synthesized compound, TOK-8801 (N-(2-phenylethyl)-3,6,6-trimethyl-5,6-dihydroimidazo [2,1-b]thiazole-2-carboxamide) on antibody production in vivo and delayed-type hypersensitivity in mice. Int J Immunopharmacol. 1990;12(5):497-502.

Background

TOK-8801 is a synthesized dihydroimidazothiazole carboxamide and is under development as an immunomodulator.

TOK-8801 is a synthesized dihydroimidazothiazole carboxamide and is under development as an immunomodulator. TOK-8801 augments the in vitro anti-SRBC PFC response of murine splenocytes in a bell-shaped manner. The stimulatory effect of TOK-8801 is observed at concentrations of 2.5×10-7 to 2.5×10-5 M and is diminished at 10-4 M. The cell-viability is not altered during the culture with TOK-8801 at any doses used in this experiment (10-7 to 10-4 M). TOK-8801 enhances the 3H-TdR uptake of these responses in a bell-shaped manner, and effective concentrations of TOK-8801 are 10-7 to 10-5 M[1].

The anti-SRBC PFC response per spleen, which is prominently lowered by restraint-stress (P<0.05), is significantly restored by the administration of TOK-8801 (0.5 mg/kg, P<0.05). The number of total splenic lymphocytes in restraint-stress is decreased, but there are no significant changes in the number of total splenic lymphocytes by the treatment with TOK-8801[1]. When TOK-8801 is administered orally at doses of 0.1 to 10 mg/kg, the number of plaque forming cell (PFC) significantly decreases or tends to decrease. Treatment of TOK-8801 at doses of 0.1 to 1 mg/kg causes significant suppression in the delayed-type hypersensitivity (DTH) reaction induced in high responder[2].

[1]. Fujiwara M, et al. Immunomodulatory activity of the newly synthesized compound TOK-8801 (N-(2-phenylethyl)-3,6,6-trimethyl-5,6-dihydroimidazo[2,1-b]thiazole-2- carboxamide). Jpn J Pharmacol. 1989 Dec;51(4):549-54. [2]. Shibata K, et al. Immunomodulatory effect of a newly synthesized compound, TOK-8801 (N-(2-phenylethyl)-3,6,6-trimethyl-5,6-dihydroimidazo [2,1-b]thiazole-2-carboxamide) on antibody production in vivo and delayed-type hypersensitivity in mice. Int J Immunopharmacol. 1990;12(5):497-502.

Chemical Properties

Cas No. 105963-46-0 SDF
Canonical SMILES O=C(C1=C(C)N2C(S1)=NC(C)(C)C2)NCCC3=CC=CC=C3
Formula C17H21N3OS M.Wt 315.43
Solubility Soluble in DMSO Storage Store at -20°C
General tips Please select the appropriate solvent to prepare the stock solution according to the solubility of the product in different solvents; once the solution is prepared, please store it in separate packages to avoid product failure caused by repeated freezing and thawing.Storage method and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored at -20°C, please use it within 1 month.
To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time.
Shipping Condition Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request.

Complete Stock Solution Preparation Table

Prepare stock solution
1 mg 5 mg 10 mg
1 mM 3.1703 mL 15.8514 mL 31.7028 mL
5 mM 0.6341 mL 3.1703 mL 6.3406 mL
10 mM 0.317 mL 1.5851 mL 3.1703 mL
  • Molarity Calculator

  • Dilution Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
**When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / CoA (available online).

Calculate

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.

Reviews

Review for TOK-8801

Average Rating: 5 ★★★★★ (Based on Reviews and 32 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for TOK-8801

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.